From: Systematic review of case reports on COVID-19 associated myocarditis: a discussion on treatments
Treatments | Total | % (number of cases/ total cases) |
---|---|---|
Steroids | ||
Methylprednisolone | 40 | 27.4 |
Dexamethasone | 15 | 10.3 |
Prednisone | 14 | 9.6 |
Anti-virals | ||
Remdesivir | 11 | 7.5 |
Chloroquine/ hydroxychloroquine | 19 | 13 |
NSAIDS | ||
Colchicine | 21 | 14.4 |
Aspirin | 31 | 21.2 |
Ibuprofen | 9 | 6.1 |
Surgical | ||
Use of ECMO | 28 | 19.2 |
Implantable devices | 14 | 9.6 |
Catheterization | 5 | 3.4 |
Pericardiocentesis | 6 | 4.1 |
Immune drugs | ||
Intravenous immunoglobulin | 38 | 26 |
Tocilizumab | 12 | 8.2 |
Interferon | 1 | 0.7 |
Anakinra | 9 | 6.2 |
Cardiac drugs | ||
Use of anticoagulants | 42 | 28.8 |
Inotropes | 37 | 25.3 |
Vasopressors | 46 | 31.5 |
Angiotensin-II receptor blocker | 1 | 0.7 |
ACE Inhibitor | 13 | 8.9 |
Beta-blocker | 23 | 15.8 |
Anti-Arrhythmic | 11 | 7.5 |
Other | ||
Diuretics | 22 | 15.1 |
Unspecified anti-inflammatory | 5 | 3.4 |
Antibiotics | 59 | 40.4 |
Unspecified Steroids | 15 | 10.3 |
Unspecified anti-virals | 13 | 8.9 |
Hydrocortisone | 3 | 2.1 |
Acetaminophen | 4 | 2.7 |
Mineralocorticoid antagonist | 2 | 1.4 |